ClinicalTrials.gg
TerminatedNCT04197986PROOF302Updated Mar 13, 2024Results posted

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations

A Phase 3 interventional study of Infigratinib and Placebo in Upper Tract Urothelial Carcinomas and Urothelial Bladder Cancer, sponsored by QED Therapeutics, Inc.. Terminated at 143 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-13.

Sponsored by QED Therapeutics, Inc. (part of BridgeBio) · Phase 3, Interventional, and Treatment

Why this study was terminated
The sponsor has decided to close the study due to the discontinuation of infigratinib development. The discontinuation of the study was not due to safety reasons.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 881 studies in Urinary Bladder Neoplasms with a site in United States — 162 open to participants now, 268 under way, 31 of them phase 3. Urinary Bladder Neoplasms · United States.

Enrollment
399th of 714
39 · median 46
Started
2020
with 52 others
Phase 3
79 of 881
12 open now
Registered
573rd of 881
by date

Among the 881 studies in Urinary Bladder Neoplasms with a site in United States, this one is the 399th largest by enrollment of the 714 interventional ones that give a count, is one of 53 that started in 2020, is one of 79 in phase 3, and was the 573rd registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

162 of the 881 studies in Urinary Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 881 studies in Urinary Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy of infigratinib (an oral targeted FGFR1-3 inhibitor) versus placebo, as adjuvant treatment following surgery in adult subjects with invasive urothelial carcinoma and susceptible FGFR3 genetic alterations (mutations, and gene fusions or rearrangements) who have disease that is considered at high risk for recurrence with surgery alone. The study enrolls subjects with either bladder cancer post radical cystectomy or upper tract urothelial cancer post distal ureterectomy and/or nephrectomy. Study treatment is randomized 1:1 between infigratinib or placebo with treatment up to 1 year or until invasive local, distal, or metastatic disease recurrence confirmed by independent imaging reviewer.

03

Conditions studied

  • Upper Tract Urothelial Carcinomas
  • Urothelial Bladder Cancer

Keywords

  • FGFR3 Genetic Alterations
  • Upper Tract Urothelial Carcinomas
  • UTUC
  • Muscle Invasive Urothelial Carcinoma
  • Fibroblast Growth Factor Receptor Inhibitor
  • BGJ398
  • FGFR3
  • Urothelial Bladder Cancer
  • UBC
  • Infigratinib Phosphate
  • Infigratinib
  • Adjuvant
  • Nephroureterectomy
  • Distal ureterectomy
  • Cystectomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  1. Are randomized within 120 days following nephroureterectomy, distal ureterectomy or cystectomy.
  2. Have or cytologically confirmed, invasive urothelial carcinoma with susceptible FGFR3 alterations. Variant histology is allowed provided urothelial carcinoma is predominant (>50%). Neuroendocrine (including small and large cell), sarcomatoid, and plasmacytoid variants are excluded (any component).

    1. Regarding samples and documentation of FGFR3

      • i. FGFR3 mutation is confirmed if: FGFR3 gene is mutated in Exon 7 (R248C, S249C), Exon 10 (G370C, A391E, Y373C), or Exon 15 (K650M/T, K650E/Q)

      OR

      • ii. FGFR3 gene fusion or FGFR3 rearrangement is confirmed based on the following genomic criteria if:

        • Any fusion/rearrangement with a literature-derived known partner gene regardless of strand or frame.
        • Fusion/rearrangements in the same strand that are in frame with a novel partner gene.
        • Fusion/rearrangements with one breakpoint in the intron 17 - exon 18 hotspot region and the other breakpoint in an intergenic region or another gene. This rule excludes 3' duplications comprising only exon 18.
      • iii. The amino acid numbers for the FGFR3 mutations refer to the functional FGFR3 isoform 1 (NP_000133.1) that is the NCBI Refseq ID used to report genetic alterations in FGFR3 by the FoundationOne® CDx test (F1CDx, Foundation Medicine, USA).
      • iv. FGFR3 alteration must be confirmed by Foundation Medicine for F1CDx testing:

        • The tumor sample to be used should be from the definitive surgical resection (cystectomy, nephroureterectomy, or distal ureterectomy), or from an archival of confirmed invasive urothelial carcinoma (≥pT2).
    2. If status post chemotherapy, pathologic stage at surgical resection must be Stage ≥ ypT2 and/or yN+. Prior neoadjuvant therapy is defined as at least 3 cycles of neoadjuvant cisplatin-based chemotherapy with a planned cisplatin dose of 70 mg/m2/cycle. Subjects who received less than this or non-cisplatin-based neoadjuvant treatment are not excluded.
    3. If not status post neoadjuvant chemotherapy, is ineligible to receive cisplatin-based adjuvant chemotherapy based on Galsky criteria:
    4. Subjects who refuse cisplatin-based chemotherapy or who are ineligible to receive cisplatin-based chemotherapy based on Galsky criteria must also meet the following criteria:
    5. Must have a centrally reviewed negative postoperative computed tomography (CT) (defined as lymph nodes with short axis \<1.0 cm and without growth and no distant according to [ v1.1 criteria or negative biopsy within 28 days before randomization to confirm absence of disease at baseline.
  3. Have (ECOG) performance status of ≤2.
  4. If a woman of , must have a negative pregnancy test within 7 days of the first dose of study drug. Sexually active males must use a condom during intercourse while taking study drug and for 1 month after the last dose of study drug and should not father a child during this period

Key Exclusion Criteria:

  1. Presence of positive invasive surgical margins following nephroureterectomy, distal ureterectomy, or cystectomy. In subjects not eligible for further surgery, radiotherapy, or other efficacious treatment, microscopic positive noninvasive margins (eg, carcinoma in situ) without gross residual disease are allowed.
  2. Have received Bacillus Calmette-Guerin (BCG) or other intravesical therapy for Non-Muscle Invasive Bladder Cancer (NMIBC) within the previous 30 days.
  3. Are currently receiving or are planning to receive during participation in this study, treatment with agents that are known moderate or strong inducers or inhibitors of and medications which increase serum phosphorus and/or calcium concentration. Prior anticancer or other therapies are restricted as follows:

    1. Prior adjuvant treatment for urothelial cancer is not allowed.
    2. Prior neoadjuvant therapy (eg, chemotherapy, immunotherapy, or ) is allowed if inclusion criterion #4 is met. Prior neoadjuvant chemotherapy must have been completed within a period of time that is greater than the cycle length used for that treatment before first dose of study drug.
    3. Prior biologic, immunotherapy, or investigational therapy should have been completed within a period that is ≥5 half-lives or 30 days, whichever is shorter, before the first dose of study drug.
  4. Have previously or currently is receiving treatment with a mitogen-activated protein kinase (MEK) or selective FGFR inhibitor.
  5. Have a history of primary within the past 3 years other than (1) invasive UBC or UTUC (ie, disease under study), (2) noninvasive urothelial carcinoma, (3) any adequately treated in situ carcinoma or non-melanoma carcinoma of the skin, (4) any other curatively treated malignancy that is not expected to require treatment for recurrence during participation in the study, or (5) an untreated cancer on active surveillance that may not affect the subject's survival status for ≥3 years based on clinician assessment/statement and with medical monitor approval.
  6. Have current evidence of corneal keratopathy or retinal disorder confirmed by ophthalmic examination. Subjects with asymptomatic ophthalmic conditions assessed by the investigator to pose minimal risk for study participation may be enrolled in the study.
  7. Have a history and/or current evidence of extensive tissue calcification
  8. Have impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral infigratinib
  9. Have current evidence of endocrine alterations of calcium/phosphate homeostasis (eg, parathyroid disorders, history of parathyroidectomy, tumor lysis, tumoral calcinosis), unless well controlled.
  10. Have consumed grapefruit, grapefruit juice, grapefruit hybrids, pomegranates, star fruits, pomelos, or Seville oranges or products containing juice of these fruits within 7 days before the first dose of study drug; have taken any Chinese herbal medicine or Chinese patent medicine treatments with anticancer activity within 14 days of the first dose of study drug.
  11. Have insufficient bone marrow function:

    1. (ANC) \<1,000/mm3 (1.0 × 109/L).
    2. \<75,000/mm3 (\<75 × 109/L).
    3. \<8.5 g/dL; transfusion support is allowed if >1 week before randomization and hemoglobin remains stable.
  12. Have insufficient hepatic and renal function:

    1. Total >1.5 × (ULN) of the testing laboratory (for subjects with documented Gilbert syndrome, direct bilirubin must be ≤1.5 × ULN and enrollment requires approval by the medical monitor).
    2. /SGOT and ALT/SGPT >2.5 × ULN of the testing laboratory.
    3. Serum creatinine >1.5 × ULN or a calculated or measured of \<30 mL/min.
  13. Have amylase or lipase >2.0 × ULN.
  14. Have abnormal calcium or phosphorus:

    1. Inorganic phosphorus higher than 1.02 × ULN of the testing laboratory.
    2. Total serum calcium (can be corrected) higher than 1.02 × ULN of the testing laboratory.
  15. Have cardiac disease including any of the following:

    1. (NYHA) Class ≥2B; subjects with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the NYHA classification.
    2. Uncontrolled hypertension
    3. Presence of v5.0 Grade ≥2 ventricular arrhythmias, atrial fibrillation, bradycardia, or conduction abnormality.
    4. Unstable angina pectoris or acute myocardial infarction ≤3 months before the first dose of study drug.
    5. Average >470 msec (males and females). Note: If the QTcF is >470 msec in the first , a total of 3 ECGs separated by ≥5 minutes should be performed. If the average of these 3 consecutive results for QTcF is ≤470 msec, the subject meets eligibility in this regard.
    6. History of congenital long QT syndrome.
  16. Have had a recent (≤3 months before the first dose of study drug) or stroke.
  17. If female, are pregnant or nursing (lactating).
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Infigratinib 125 mg

    Participants will be randomly assigned (1:1) to receive oral infigratinib administered once daily for the first 3 weeks (21 days) of each 28-day cycle for a maximum of 52 weeks

    Drug: Infigratinib

  • Placebo comparator
    Placebo

    Participants will be randomly assigned (1:1) to receive oral placebo administered once daily for the first 3 weeks (21 days) of each 28-day cycle for a maximum of 52 weeks

    Drug: Placebo

Interventions

  • Participants randomly assigned to infigratinib will receive hard gelatin capsules for oral administration of infigratinib 125 mg once a day (administered as one 100-mg capsule and one 25-mg capsule) using a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.

    Also known as: IP, Study drug

  • DrugPlacebo

    Participants randomly assigned to placebo will receive placebo matching in appearance the investigational product (infigratinib), which will be provided as hard gelatin capsules for oral use and will be administered once daily on a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.

06

What researchers measure

Primary outcomes

  1. Centrally Determined Disease-free Survival (DFS)

    DFS was defined as the number of months from date of randomization to local/regional invasive or metastatic recurrence or death due to any cause (referred as DFS event), whichever occurs earlier. Due to early termination of the study by the sponsor, results will focus primarily on the primary and key secondary endpoints of the study. Due to early termination of the study by the sponsor, data were censored for 85.0% to 89.5% of all subjects. Data cutoff 28 Feb 2023.

    Time frame: The number of months from date of randomization to local/regional invasive or metastatic recurrence or death due to any cause.

Secondary outcomes

  1. Investigator-assessed DFS

    DFS was defined as the number of months from date of randomization to local/regional invasive or metastatic recurrence or death due to any cause (referred as DFS event), whichever occurs earlier. Due to early termination of the study by the sponsor, data were censored for 85.0% to 89.5% of all subjects. Data cutoff 28 Feb 2023.

    Time frame: The number of months from date of randomization to local/regional invasive or metastatic recurrence or death due to any cause.

  2. Metastasis-free Survival (MFS)

    MFS was defined as the time from randomization to any metastatic recurrence as determined by the investigator, or death due to any cause, whichever occurred earlier. Due to early termination of the study by the sponsor, data were censored for 85.0% to 89.5% of all subjects. Data cutoff 28 Feb 2023.

    Time frame: The time from randomization to any metastatic recurrence as determined by the investigator, or death due to any cause.

  3. Overall Survival (OS)

    Overall survival time was defined as the number of months from randomization to death. Due to early termination of the study by the sponsor, data were censored for 85.0% to 89.5% of all subjects. Data cutoff 28 Feb 2023.

    Time frame: The number of months from randomization to death.

  4. Investigator-reviewed DFS Including Intraluminal Low-Risk Recurrence

    Investigator assessment of intraluminal low-risk recurrence as assessed by DFS. Due to early termination of the study by the sponsor, data were censored for 85.0% to 89.5% of all subjects. Data cutoff 28 Feb 2023.

    Time frame: The number of months from date of randomization to local/regional invasive or metastatic recurrence or death due to any cause.

  5. Number of Participants With Adverse Events (AEs)

    Number of participants with AEs

    Time frame: From first dose to last dose of study treatment +30 days (an average of 4 months for the infigratinib arm and 8 months for the placebo arm).

  6. Number of Participants With Serious Adverse Events (SAEs)

    Number of Participants with SAEs

    Time frame: From first dose to last dose of study treatment +30 days (an average of 4 months for the infigratinib arm and 8 months for the placebo arm)

07

Results

Posted Mar 13, 2024

Participant flow

Participants with a diagnosis of invasive urothelial carcinoma were recruited to this double-blind, randomized, placebo-controlled global study across 30 study centers (11 in North America, and 19 in Western Europe) based on documented evidence of FGFR3 genetic alteration. The first participant was treated on 18 March 2020. The data cutoff for the primary analysis was 28 February 2023.

Participant flow — Overall Study
MilestoneInfigratinib 125 mgPlacebo
Started2019
Treatment ended2019
Completed2019
Not completed00

Outcome measures

PrimaryCentrally Determined Disease-free Survival (DFS)

DFS was defined as the number of months from date of randomization to local/regional invasive or metastatic recurrence or death due to any cause (referred as DFS event), whichever occurs earlier. Due to early termination of the study by the sponsor, results will focus primarily on the primary and key secondary endpoints of the study. Due to early termination of the study by the sponsor, data were censored for 85.0% to 89.5% of all subjects. Data cutoff 28 Feb 2023.

Time frame:
The number of months from date of randomization to local/regional invasive or metastatic recurrence or death due to any cause.
Reported as:
Median · Months
Centrally Determined Disease-free Survival (DFS)
MonthsInfigratinib 125 mgPlacebo
Centrally Determined Disease-free Survival (DFS)5.3 (0.03 to 17.48)5.4 (0.03 to 20.90)
SecondaryInvestigator-assessed DFS

DFS was defined as the number of months from date of randomization to local/regional invasive or metastatic recurrence or death due to any cause (referred as DFS event), whichever occurs earlier. Due to early termination of the study by the sponsor, data were censored for 85.0% to 89.5% of all subjects. Data cutoff 28 Feb 2023.

Time frame:
The number of months from date of randomization to local/regional invasive or metastatic recurrence or death due to any cause.
Reported as:
Median · Months
Investigator-assessed DFS
MonthsInfigratinib 125 mgPlacebo
Investigator-assessed DFS6.39 (0.03 to 18.07)12.22 (0.03 to 21.36)
SecondaryMetastasis-free Survival (MFS)

MFS was defined as the time from randomization to any metastatic recurrence as determined by the investigator, or death due to any cause, whichever occurred earlier. Due to early termination of the study by the sponsor, data were censored for 85.0% to 89.5% of all subjects. Data cutoff 28 Feb 2023.

Time frame:
The time from randomization to any metastatic recurrence as determined by the investigator, or death due to any cause.
Reported as:
Median · Months
Metastasis-free Survival (MFS)
MonthsInfigratinib 125 mgPlacebo
Metastasis-free Survival (MFS)6.5 (0.03 to 18.07)12.2 (0.03 to 21.36)
SecondaryOverall Survival (OS)

Overall survival time was defined as the number of months from randomization to death. Due to early termination of the study by the sponsor, data were censored for 85.0% to 89.5% of all subjects. Data cutoff 28 Feb 2023.

Time frame:
The number of months from randomization to death.
Reported as:
Median · Months
Overall Survival (OS)
MonthsInfigratinib 125 mgPlacebo
Overall Survival (OS)13.1 (0.76 to 32.07)16.7 (1.22 to 31.57)
SecondaryInvestigator-reviewed DFS Including Intraluminal Low-Risk Recurrence

Investigator assessment of intraluminal low-risk recurrence as assessed by DFS. Due to early termination of the study by the sponsor, data were censored for 85.0% to 89.5% of all subjects. Data cutoff 28 Feb 2023.

Time frame:
The number of months from date of randomization to local/regional invasive or metastatic recurrence or death due to any cause.
Reported as:
Median · Months
Investigator-reviewed DFS Including Intraluminal Low-Risk Recurrence
MonthsInfigratinib 125 mgPlacebo
Investigator-reviewed DFS Including Intraluminal Low-Risk Recurrence5.29 (0.03 to 18.07)5.62 (0.03 to 20.90)
SecondaryNumber of Participants With Adverse Events (AEs)

Number of participants with AEs

Time frame:
From first dose to last dose of study treatment +30 days (an average of 4 months for the infigratinib arm and 8 months for the placebo arm).
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsInfigratinib 125 mgPlacebo
Number of Participants With Adverse Events (AEs)1916
SecondaryNumber of Participants With Serious Adverse Events (SAEs)

Number of Participants with SAEs

Time frame:
From first dose to last dose of study treatment +30 days (an average of 4 months for the infigratinib arm and 8 months for the placebo arm)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsInfigratinib 125 mgPlacebo
Number of Participants With Serious Adverse Events (SAEs)22

Adverse events

Collected over From first administration of study treatment and up to last administration of study treatment + 30 days (an average of 4 months for the infigratinib arm and 8 months for the placebo arm).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Infigratinib 125 mg2/20 (10%)2/20 (10%)19/20 (95%)
Placebo1/19 (5.3%)2/19 (10.5%)16/19 (84.2%)
Most frequent serious events
Most frequent serious events
EventInfigratinib 125 mgPlacebo
DiarrhoeaGastrointestinal disorders2/200/19
UrosepsisInfections and infestations0/201/19
Urinary tract obstructionRenal and urinary disorders0/201/19
LymphoceleVascular disorders0/201/19
VomitingGastrointestinal disorders1/200/19
DehydrationMetabolism and nutrition disorders1/200/19
Chronic kidney diseaseRenal and urinary disorders1/200/19
Most frequent other events
Showing 10 of 18
Most frequent other events
EventInfigratinib 125 mgPlacebo
DiarrhoeaGastrointestinal disorders12/202/19
HyperphosphataemiaMetabolism and nutrition disorders12/200/19
Blood creatinine increasedInvestigations9/203/19
AlopeciaSkin and subcutaneous tissue disorders8/200/19
Dry mouthGastrointestinal disorders7/201/19
FatigueGeneral disorders6/203/19
COVID-19Infections and infestations0/205/19
DysgeusiaNervous system disorders5/200/19
Mucosal inflammationGeneral disorders4/202/19
Lipase increasedInvestigations4/201/19

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)InfigratinibPlaceboTotal
Age Group — <=18 years000
Age Group — Between 18 and 65 years8412
Age Group — >=65 years121527
Age, Continuous
Age, Continuous(years)InfigratinibPlaceboTotal
Mean66.1 ± 12.1069.7 ± 12.7567.8 ± 12.39
Sex: Female, Male
Sex: Female, Male(Participants)InfigratinibPlaceboTotal
Female246
Male181533
Race (NIH/OMB)
Race (NIH/OMB)(Participants)InfigratinibPlaceboTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American101
White171633
More than one race022
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(participants)InfigratinibPlaceboTotal
North America8614
Europe121325
BMI
BMI(kg/m2)InfigratinibPlaceboTotal
Mean27.78 ± 4.88226.05 ± 4.79326.96 ± 4.850
ECOG PS
ECOG PS(Participants)InfigratinibPlaceboTotal
0151126
15813
Primary Site of Cancer
Primary Site of Cancer(Participants)InfigratinibPlaceboTotal
UTUC111223
UBC9716

11 further baseline measures are reported on the registry.

08

Study locations

143 sites
  • Arizona Oncology Associates
    Tucson, Arizona 85711, United States
  • City of Hope - Duarte
    Duarte, California 91010, United States
  • City of Hope
    Duarte, California 91010, United States
  • Loma Linda University Faculty Medical Clinics
    Loma Linda, California 92350, United States
  • USC Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
  • The Urology Center of Colorado
    Denver, Colorado 80211, United States
  • Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • Urological Research Network CORP
    Hialeah, Florida 33016, United States
  • Mayo Clinic - Jacksonville
    Jacksonville, Florida 32224, United States
  • Lakeland Regional Health Hollis Cancer Center
    Lakeland, Florida 33805, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • UChicago Medicine Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
    Chicago, Illinois 60637, United States
  • DuPage Medical Group - Warrenville Road
    Lisle, Illinois 60532, United States
  • Indiana University Melvin and Bren Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • Tulane University/Southeastern Louisiana VA Health Care
    New Orleans, Louisiana 70112, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Saint Louis University- SLUCare Academic Pavilion
    Saint Louis, Missouri 63110, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03766, United States
  • John Theurer Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • New Jersey Urology - Saddle Brook
    Saddle Brook, New Jersey 07663, United States
  • New Jersey Urology
    Voorhees, New Jersey 08043, United States
  • Albany Medical Center - Division of Urology
    Albany, New York 12208, United States
  • Associated Medical Professionals - Syracuse
    Syracuse, New York 13210, United States
  • Duke University Cancer Center
    Durham, North Carolina 27710, United States
  • Accellacare-DuPage Medical Group
    Raleigh, North Carolina 27609, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • University of Toledo
    Arlington, Ohio 43606, United States
  • Oncology Hematology Care
    Cincinnati, Ohio 45242, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • The Ohio State University College of Medicine
    Columbus, Ohio 43210, United States
  • The University of Toledo Medical Center
    Toledo, Ohio 43614, United States
  • Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Urology Associates
    Nashville, Tennessee 37209, United States
  • Harold C. Simmons Comprehensive Cancer Center
    Dallas, Texas 75390, United States
  • Bayor College of Medicine
    Houston, Texas 77030, United States
  • Houston Methodist Hospital- Department of Urology
    Houston, Texas 77030, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • UT Southwestern
    Richardson, Texas 75080, United States
  • Urology San Antonio
    San Antonio, Texas 78229, United States
  • Huntsman Cancer Institute and Hospital
    Salt Lake City, Utah 84112, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • West Virginia University
    Morgantown, West Virginia 26506, United States
  • CHU de Liège - Sart Tilman
    Liège, Liège/Belgium 4000, Belgium
  • ZNA Middelheim
    Antwerpen, Belgium
  • Cliniques Universitaires Saint-Luc
    Brussel, 1200, Belgium
  • Universitair Ziekenhuis Leuven
    Leuven, Belgium
  • University Multiprofile Hospital For Active Treatment Deva Maria
    Burgas, 8001, Bulgaria
  • University Multiprofile Hospital For Active Treatment Dr. Georgi Stranski EAD
    Pleven, Bulgaria
  • Multiprofile Hospital For Active Treatment "Sveta Sofia"
    Sofia, Bulgaria
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • BC Cancer- Vancouver
    Vancouver, British Columbia V5Z 4E6, Canada
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G2M9, Canada
  • McGill University Health Centre (MUHC)
    Montréal, Quebec H4A 3J1, Canada
  • CHU de Québec Université Laval
    Québec, G1R 2J6, Canada
  • BC Cancer - Vancouver
    Vancouver, Canada
  • Hôpital Universitaire Pitié Salpêtrière
    Paris, Ile-de-France 75013, France
  • Hôpital Européen Georges-Pompidou
    Paris, Ile-de-France 75015, France
  • CHU de Nantes Hopital Hotel Dieu
    Paris, Paris/France 75018, France
  • Centre de Lutte Contre le Cancer - Centre Léon Bérard
    Lyon, Rhone-Alpes 69008, France
  • Institut de Cancerologie Strasbourg Europe
    Strasbourg, Strasbourg/France 67200, France
  • Institut Claudius Regaud
    Toulouse, Toulouse/France 31059, France
  • Gustave Roussy
    Villejuif, Villejuif/France 94805, France
  • Hôpital Morvan
    Brest, 29200, France
  • CHU de Nantes Hopital Hotel Dieu
    Nantes, France
  • Hopital Bichat - Claude - Bernard
    Paris, France
  • Centre Eugène Marquis
    Rennes, 35042, France
  • Centre Hospitalier Privé Saint-Grégoire
    Saint-Grégoire, 35760, France
  • Institut De Cancerologie De L'ouest - Site Saint-Herblain
    Saint-Herblain, France
  • Clinique Mutualiste de l'Estuaire
    Saint-Nazaire, 44600, France
  • Gustave Roussy
    Villejuif, France
  • Charité - Universitatsmedizin Berlin
    Berlin, Berlin/Germany 10117, Germany
  • Universitätsklinikum Düsseldorf
    Duesseldorf, Nordrhein-Westfalen 40225, Germany
  • Urologicum Duisburg
    Duisburg, Nordrhein-WestFalen 47179, Germany
  • Universitätsklinikum Essen
    Essen, Nordrhein-Westfalen 45147, Germany
  • Marien Hospital Herne - Universitätsklinikum der Ruhr-Universität Bochum
    Herne, Nordrhein-Westfalen 44625, Germany
  • Charite Universitaetsmedizin Berlin
    Berlin, Germany
  • Urologie
    Berlin, Germany
  • University Hospital Duesseldorf
    Duesseldorf, Germany
  • Universitatsklinikum des Saarlandes Klinik fur Urologie & Kinderurologie
    Homburg/saar, Germany
  • Universitätsklinikum des Saarlandes Klinik für Urologie & Kinderurologie
    Homburg, Germany
  • Universitatsklinikum Magdeburg
    Magdeburg, Germany
  • Caritas-Krankenhaus St. Josef Klinik für Urologie
    Regensburg, 93053, Germany
  • Universitätsklinikum Tübingen
    Tübingen, Germany
  • Henry Dunant Hospital Center
    Athens, Attica 11526, Greece
  • Bioclinic Thessalonikis
    Thessaloníki, Makedonia 54622, Greece
  • Anassa General Clinic
    Volos, Greece
  • Ospedale di Cremona
    Cremona, Cremona/Italy 26100, Italy
  • Ospedale Policlinico San Martino
    Genova, Genova/Italy 16132, Italy
  • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
    Meldola, Meldola/Italy 47014, Italy
  • Istituto Europeo di Oncologia
    Milano, Milano/Italy 20141, Italy
  • Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
    Napoli, Naples 80131, Italy
  • Azienda Ospedaliero-Universitaria Pisana
    Pisa, Pisa/italy 56126, Italy
  • IRCCS Centro di Riferimento Oncologico di Basilicata
    Rionero In Vulture, Potenza 85028, Italy
  • Arcispedale Santa Maria Nuova
    Reggio Emilia, Reggio Emilia/Italy 42100, Italy
  • Università Campus Bio-Medico di Roma
    Roma, Roma/Italy 00128, Italy

Showing the first 100 of 143 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Pal SK, Somford DM, Grivas P, Sridhar SS, Gupta S, Bellmunt J, Sonpavde G, Fleming MT, Lerner SP, Loriot Y, Hoffman-Censits J, Valderrama BP, Andresen C, Schnabel MJ, Cole S, Daneshmand S. Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial. Future Oncol. 2022 Jul;18(21):2599-2614. doi: 10.2217/fon-2021-1629. Epub 2022 May 24. PubMed 35608106 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Feb 2023, 35 months.

Results were first posted in Mar 2024, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2019
First posted
Dec 13, 2019
StartActual
Mar 11, 2020
Primary completionActual
Feb 28, 2023
CompletionActual
Feb 28, 2023
Results first posted
Mar 13, 2024
Last update
Mar 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04197986
Responsible party
Sponsor
First posted
Dec 13, 2019
Start date
Mar 11, 2020
Primary completion
Feb 28, 2023
Completion
Feb 28, 2023
Results posted
Mar 13, 2024
Last update
Mar 13, 2024

Study contacts

David van Veenhuyzen, M.B., Ch.B., M.Pharm.Med.
study director · QED Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Infigratinib

Start the discussion